Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8831768rdf:typepubmed:Citationlld:pubmed
pubmed-article:8831768lifeskim:mentionsumls-concept:C0001128lld:lifeskim
pubmed-article:8831768lifeskim:mentionsumls-concept:C0014898lld:lifeskim
pubmed-article:8831768lifeskim:mentionsumls-concept:C0170657lld:lifeskim
pubmed-article:8831768lifeskim:mentionsumls-concept:C0596902lld:lifeskim
pubmed-article:8831768lifeskim:mentionsumls-concept:C0220781lld:lifeskim
pubmed-article:8831768lifeskim:mentionsumls-concept:C1167622lld:lifeskim
pubmed-article:8831768lifeskim:mentionsumls-concept:C1883254lld:lifeskim
pubmed-article:8831768lifeskim:mentionsumls-concept:C0243071lld:lifeskim
pubmed-article:8831768lifeskim:mentionsumls-concept:C0871161lld:lifeskim
pubmed-article:8831768lifeskim:mentionsumls-concept:C1611588lld:lifeskim
pubmed-article:8831768pubmed:issue20lld:pubmed
pubmed-article:8831768pubmed:dateCreated1996-11-14lld:pubmed
pubmed-article:8831768pubmed:abstractTextNew methods for the synthesis of 3 beta-(4'-alkyl-, 4'-alkenyl-, and 4'-alkynylphenyl)nortropane-2 beta-carboxylic acid methyl esters 2-4, respectively, were developed. These methods involved coupling of the appropriate organometallic reagents to 3 beta-(4'-iodophenyl)tropane-2 beta-carboxylic acid methyl ester (6a, RTI-55) or to an N-protected derivative of 6a followed by N-demethylation or removal of the protecting group. Some analogs were prepared by catalytic reduction of the alkene and alkene analogs 3 and 4 or by isomerization of the alkenes 3. The analogs 2-4 were evaluated for inhibition of radioligand binding to the serotonin (5-HT), dopamine (DA), and norepinephrine (NE) transporters. 3 beta-(4'-Isopropenyl- and 4'-cis-propenylphenyl)nortropane-2 beta-carboxylic acid methyl esters (3b,d), which possessed IC50 values of 0.6 and 1.15 nM, respectively, were the most potent analogs at the 5-HT transporter, and with NE/5-HT IC50 ratios of 240 and 128 nM, respectively, they were selective for the 5-HT relative to the NE transporter. Since interaction with the serotonin transporter may modulate the pharmacological effects resulting from binding to the dopamine transporter, 3 beta-(4'-isopropenylphenyl)tropane-2 beta-carboxylic acid methyl ester (11b) which has good affinity for both the 5-HT and DA transporters but low affinity at the NE transporter may be useful for studying this interaction.lld:pubmed
pubmed-article:8831768pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8831768pubmed:languageenglld:pubmed
pubmed-article:8831768pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8831768pubmed:citationSubsetIMlld:pubmed
pubmed-article:8831768pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8831768pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8831768pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8831768pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8831768pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8831768pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8831768pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8831768pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8831768pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8831768pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8831768pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8831768pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8831768pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8831768pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8831768pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8831768pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8831768pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8831768pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8831768pubmed:statusMEDLINElld:pubmed
pubmed-article:8831768pubmed:monthSeplld:pubmed
pubmed-article:8831768pubmed:issn0022-2623lld:pubmed
pubmed-article:8831768pubmed:authorpubmed-author:CarrollF IFIlld:pubmed
pubmed-article:8831768pubmed:authorpubmed-author:KuharM JMJlld:pubmed
pubmed-article:8831768pubmed:authorpubmed-author:LewisA AAAlld:pubmed
pubmed-article:8831768pubmed:authorpubmed-author:AbrahamPPlld:pubmed
pubmed-article:8831768pubmed:authorpubmed-author:BojaJ WJWlld:pubmed
pubmed-article:8831768pubmed:authorpubmed-author:BloughB EBElld:pubmed
pubmed-article:8831768pubmed:issnTypePrintlld:pubmed
pubmed-article:8831768pubmed:day27lld:pubmed
pubmed-article:8831768pubmed:volume39lld:pubmed
pubmed-article:8831768pubmed:ownerNLMlld:pubmed
pubmed-article:8831768pubmed:authorsCompleteYlld:pubmed
pubmed-article:8831768pubmed:pagination4027-35lld:pubmed
pubmed-article:8831768pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:8831768pubmed:meshHeadingpubmed-meshheading:8831768-...lld:pubmed
pubmed-article:8831768pubmed:meshHeadingpubmed-meshheading:8831768-...lld:pubmed
pubmed-article:8831768pubmed:meshHeadingpubmed-meshheading:8831768-...lld:pubmed
pubmed-article:8831768pubmed:meshHeadingpubmed-meshheading:8831768-...lld:pubmed
pubmed-article:8831768pubmed:meshHeadingpubmed-meshheading:8831768-...lld:pubmed
pubmed-article:8831768pubmed:meshHeadingpubmed-meshheading:8831768-...lld:pubmed
pubmed-article:8831768pubmed:meshHeadingpubmed-meshheading:8831768-...lld:pubmed
pubmed-article:8831768pubmed:meshHeadingpubmed-meshheading:8831768-...lld:pubmed
pubmed-article:8831768pubmed:meshHeadingpubmed-meshheading:8831768-...lld:pubmed
pubmed-article:8831768pubmed:meshHeadingpubmed-meshheading:8831768-...lld:pubmed
pubmed-article:8831768pubmed:meshHeadingpubmed-meshheading:8831768-...lld:pubmed
pubmed-article:8831768pubmed:meshHeadingpubmed-meshheading:8831768-...lld:pubmed
pubmed-article:8831768pubmed:meshHeadingpubmed-meshheading:8831768-...lld:pubmed
pubmed-article:8831768pubmed:meshHeadingpubmed-meshheading:8831768-...lld:pubmed
pubmed-article:8831768pubmed:meshHeadingpubmed-meshheading:8831768-...lld:pubmed
pubmed-article:8831768pubmed:meshHeadingpubmed-meshheading:8831768-...lld:pubmed
pubmed-article:8831768pubmed:meshHeadingpubmed-meshheading:8831768-...lld:pubmed
pubmed-article:8831768pubmed:meshHeadingpubmed-meshheading:8831768-...lld:pubmed
pubmed-article:8831768pubmed:meshHeadingpubmed-meshheading:8831768-...lld:pubmed
pubmed-article:8831768pubmed:meshHeadingpubmed-meshheading:8831768-...lld:pubmed
pubmed-article:8831768pubmed:meshHeadingpubmed-meshheading:8831768-...lld:pubmed
pubmed-article:8831768pubmed:meshHeadingpubmed-meshheading:8831768-...lld:pubmed
pubmed-article:8831768pubmed:meshHeadingpubmed-meshheading:8831768-...lld:pubmed
pubmed-article:8831768pubmed:year1996lld:pubmed
pubmed-article:8831768pubmed:articleTitleSynthesis and transporter binding properties of 3 beta-(4'-alkyl-, 4'-alkenyl-, and 4'-alkynylphenyl)nortropane-2 beta-carboxylic acid methyl esters: serotonin transporter selective analogs.lld:pubmed
pubmed-article:8831768pubmed:affiliationChemistry and Life Sciences, Research Triangle Institute, Research Triangle Park, North Carolina 27709, USA.lld:pubmed
pubmed-article:8831768pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8831768pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:8831768lld:chembl
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8831768lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8831768lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8831768lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8831768lld:pubmed